跳至主要内容
临床试验/NCT00770237
NCT00770237已完成不适用

Effects of Smoking Cues on Tobacco Craving Responses and the Reinforcing Efficacy of Cigarettes in Smokers With and Without Schizophrenia

University of Maryland, Baltimore1 个研究点 分布在 1 个国家目标入组 44 人开始时间: 2008年10月1日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
已完成
入组人数
44
试验地点
1
主要终点
To compare the effects of smoking versus neutral cues on craving, mood, and autonomic responsivity in smokers with schizophrenia and smokers without schizophrenia.

研究概览

简要总结

In this study, we will compare cue-reactivity in smokers with and without schizophrenia and the influence of smoking cues on responding for cigarette puffs under a PR schedule of reinforcement. Given the high prevalence of smoking among individuals with schizophrenia, understanding some of the environmental factors that serve to maintain nicotine dependence is a critical step in improving smoking cessation treatment outcomes. Establishing and validating a laboratory model of cue-elicited responsivity and cigarette self- administration will allow the investigation of the efficacy of anti-craving medications in people with schizophrenia.

Specific Aims 1) To compare the effects of smoking versus neutral cues on craving, mood, and autonomic responsivity in smokers with schizophrenia and smokers without schizophrenia. 2) To compare the effects of smoking versus neutral cues on the reinforcing efficacy of tobacco cigarettes in smokers with schizophrenia and smokers without schizophrenia.

Outcome Measures During cue trials, primary measures include craving (TCQ-SF, VAS), mood (mood form, VAS), and autonomic (heart rate, blood pressure, skin conductance and temperature) responsivity. During self-administration trials, primary measures include breakpoint (final ratio completed), total number of responses, and number of cigarette puffs earned and taken. Secondary measures include baseline smoking history, mood form, TCQ-SF, CO, FTND, and urinary cotinine and 3-hydroxycotinine (3-HC).

The ratio of 3-HC/cotinine is a phenotypic biomarker of the rate of nicotine metabolism, which has been shown to be associated with level of nicotine dependence, various smoking behaviors, and treatment outcome (Ho & Tyndale, 2007). We will correlate the primary measures with the 3-HC/cotinine ratio to explore possible relationships for future study.

研究设计

研究类型
Interventional
干预模型
Crossover
主要目的
Diagnostic
盲法
Single (Participant)

入排标准

年龄范围
18 Years 至 64 Years(Adult)
性别
All
接受健康志愿者
是

入选标准

  • •Inclusion Criteria for Schizophrenia Patients
  • •18-64 year old males and females
  • •Smoking at least 10 cigarettes per day for at least 1 year
  • •Urinary cotinine level ≥ 100 ng/ml (NicAlert® reading ≥ 3)
  • •Current DSM-IV diagnosis of schizophrenia and stable medication regimen (see above)
  • •Medically healthy as determined by screening criteria
  • •Inclusion Criteria for Healthy Volunteers
  • •18-64 year old males and females
  • •Smoking at least 10 cigarettes per day for at least 1 year
  • •Urinary cotinine level ≥ 100 ng/ml (NicAlert® reading ≥ 3)
  • •Medically and psychologically healthy as determined by screening criteria

排除标准

  • •for Schizophrenia Patients
  • •Current interest in reducing or quitting tobacco use
  • •Treatment for tobacco dependence in the past 3 months
  • •Use of nicotine replacement products, bupropion, or varenicline in the past 3 months
  • •Consumption of more than 15 alcoholic drinks per week during the past month
  • •Use of any illicit drug more than twice per week during the past month
  • •Current use of any medication that would interfere with the protocol in the opinion of MAI (e.g., medications that would interfere with the cue reactivity portion of the study including, but not limited to, antidepressants, first-generation antipsychotics, and mood stabilizers)
  • •Under the influence of a drug or alcohol at experimental sessions
  • •Pregnant, nursing, or become pregnant during the study
  • •Exclusion Criteria for Healthy Volunteers
  • •Current interest in reducing or quitting tobacco use
  • •Treatment for tobacco dependence in the past 3 months
  • •Use of nicotine replacement products, bupropion, or varenicline in the past 3 months
  • •Consumption of more than 15 alcoholic drinks per week during the past month
  • •Use of any illicit drug more than twice per week during the past month
  • •Current use of any medication that would interfere with the protocol in the opinion of MAI (e.g., medications that would interfere with the cue reactivity portion of the study including, but not limited to, antidepressants, antipsychotics, and mood stabilizers)
  • •Under the influence of a drug or alcohol at experimental sessions
  • •Pregnant, nursing, or become pregnant during the study

研究组 & 干预措施

Cues

Experimental

Outcome Measures During cue trials, primary measures include craving (TCQ-SF, VAS), mood (mood form, VAS), and autonomic (heart rate, blood pressure, skin conductance and temperature) responsivity. During self-administration trials, primary measures include breakpoint (final ratio completed), total number of responses, and number of cigarette puffs earned and taken. Secondary measures include baseline smoking history, mood form, TCQ-SF, CO, FTND, and urinary cotinine and 3-hydroxycotinine (3-HC).

干预措施: Smoking Cues (Behavioral)

Cues

Experimental

Outcome Measures During cue trials, primary measures include craving (TCQ-SF, VAS), mood (mood form, VAS), and autonomic (heart rate, blood pressure, skin conductance and temperature) responsivity. During self-administration trials, primary measures include breakpoint (final ratio completed), total number of responses, and number of cigarette puffs earned and taken. Secondary measures include baseline smoking history, mood form, TCQ-SF, CO, FTND, and urinary cotinine and 3-hydroxycotinine (3-HC).

干预措施: Neutral Cues (Behavioral)

结局指标

主要结局

To compare the effects of smoking versus neutral cues on craving, mood, and autonomic responsivity in smokers with schizophrenia and smokers without schizophrenia.

时间窗: 7-10 Days

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

MPRC

Deanna L. Kelly, Pharm.D., BCPP

University of Maryland, Baltimore

研究点 (1)

Loading locations...

相似试验